Leerink Partners Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)

Analysts at Leerink Partners started coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a research report issued on Friday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $46.00 price target on the stock. Leerink Partners’ target price points to a potential upside of 153.30% from the company’s current price.

Other research analysts also recently issued reports about the stock. UBS Group initiated coverage on shares of First Tracks Biotherapeutics in a research report on Tuesday, April 21st. They set a “buy” rating and a $45.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on shares of First Tracks Biotherapeutics in a research report on Thursday. They set an “overweight” rating and a $31.00 price objective on the stock. Finally, Barclays initiated coverage on shares of First Tracks Biotherapeutics in a research report on Wednesday. They set an “overweight” rating and a $40.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $38.40.

First Tracks Biotherapeutics Stock Down 4.4%

Shares of TRAX opened at $18.16 on Friday. First Tracks Biotherapeutics has a 52 week low of $14.79 and a 52 week high of $26.80.